Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001641172-25-005242
Filing Date
2025-04-17
Accepted
2025-04-17 16:30:27
Documents
3
Period of Report
2025-04-17

Document Format Files

Seq Description Document Type Size
1 formdef14a.htm DEF 14A 1076933
2 proxy_001.jpg GRAPHIC 459924
3 proxy_002.jpg GRAPHIC 322776
  Complete submission text file 0001641172-25-005242.txt   2156063
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41184 | Film No.: 25847729
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)